(Q44231555)

1 December 2017

0 references

Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab (English)

1 reference

1 December 2017

author name string

Joseph Adrian Lumawig Buensalido

series ordinal

1

1 reference

1 December 2017

Pranatharthi H Chandrasekar

series ordinal

2

1 reference

1 December 2017

publication date

16 December 2013

1 reference

Expert Review of Anti-infective Therapy

1 December 2017

published in

1 reference

1 December 2017

volume

12

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

151-154

1 reference

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870473

Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870473

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870473

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870473

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870473

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870473

Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870473

Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870473

Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.870473

10.1586/14787210.2014.870473

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference